Describe Current Practices in Hpylori DiagnosisHpylori/KAPNCT07043881
Assessing Knowledge, Practices, Attitudes and Barriers of Puplic Population Regarding Helicobacter Pylori Infection in Upper Egypt: Cross- Sectional Study
An observational study of Describe Current Practices in Hpylori Diagnosis, run by Assiut University at 1 site in Egypt.
Trial summary
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications. Evaluate attitudes toward the importance of testing, eradication, and antibiotic resistance concerns. Describe current practices in diagnosis, treatment regimens, and follow-up. Read more about this study
- Who is it for?
- Ages 18 to 60 yearsHealthy volunteers can take part
- Conditions the study is for
- Describe Current Practices in Hpylori Diagnosis
- How many people
- 500 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Oct 2026to 1 Oct 2026
- Phase
- Observational
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 60 years
- All sexes
- Healthy volunteers accepted
- Adult
Study population: Puplic population in Upper Egypt ( Assuit, Sohag, Minya, Qena, Luxor, Aswan) will answer validated, self-administered questionnaire (paper-based in Arabic).
Who may be able to join
- Non medical personnels.
- Age more than 18 years old e.g: patients, relatives of patients...etc.
- All persons who provided informed consent were included in this study.
Who cannot join
- All medical staff members
Trial locations and contacts
1 site in 1 country.
About this study
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications.
Evaluate attitudes toward the importance of testing, eradication, and antibiotic resistance concerns.
Describe current practices in diagnosis, treatment regimens, and follow-up. Identify barriers (e.g., access to tests, cost, training) impacting management.
Read the detailed description
Helicobacter pylori (H. pylori) is a gram-negative bacterium that colonizes the human stomach and is known for its role in the development of various gastrointestinal diseases. It is a major etiological factor in chronic peptic ulcer disease, which includes both gastric and duodenal ulcers.
The bacterium's ability to survive in the acidic environment of the stomach is facilitated by its production of urease, which neutralizes stomach acid. Chronic infection with H. pylori can lead to severe complications such as peptic ulcers, gastritis, and chronic indigestion (dyspepsia) making it a significant public health concern worldwide. It can lead to serious conditions such as stomach cancer (gastric adenocarcinoma) and mucosa-associated lymphoid tissue (MALT) lymphoma.
Helicobacter Pylori is one of the most common chronic infections that infect approximately 4.4 billion individuals worldwide. The area with the highest reported prevalence was reported in Africa (70.1%) while the lowest prevalence was reported in Switzerland (18.9%). The prevalence of HP shows large geographical variation with infection rates much higher in developing countries (in some areas > 85 %) than in Europe and North America (approximately 30%-40%). In various developing countries, more than 80% of the population is HP positive, even at young ages.
The significance of conducting research on H. pylori lies in its substantial burden on global health. Peptic ulcer disease and gastric cancer, both of which are associated with H. pylori infection, result in considerable morbidity and mortality.
Understanding the epidemiology, transmission dynamics, and pathogenic mechanisms of H. pylori is crucial for developing better prevention and treatment strategies. Additionally, research into antibiotic resistance patterns is essential for informing clinical practice and ensuring the continued efficacy of eradication regimens. Current research has extensively documented the global prevalence of H. pylori, with infection rates varying widely across different regions and populations.
Despite its widespread occurrence, there is a need to explore the knowledge and awareness of this infection within specific demographic segments, such as the urban population of Upper Egypt.
The level of awareness and knowledge about H. pylori in urban settings is crucial for public health initiatives, as it can inform targeted educational programs and interventions.
The urban population of the Upper Egypt, marked by diverse lifestyles and healthcare access, may exhibit unique patterns of awareness and knowledge regarding HP.
Factors such as cultural practices, dietary habits, and healthcare-seeking behavior can influence the prevalence of knowledge about the infection. Additionally, considering the rapid urbanization and lifestyle changes in Upper Egypt, exploring the awareness of H. pylori becomes increasingly relevant for developing effective preventive measures and promoting early detection.
What is being measured
The primary outcome is the main question the study is designed to answer.
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications.
Validated, self-administered questionnaire (paper-based in Arabic).
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Jun 2025
- Study start1 Oct 2026
- Primary completion1 Oct 2026
- Study completion1 Oct 2026
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Describe Current Practices in Hpylori DiagnosisStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Case only
- Time perspective
- Prospective
- Enrolment
- 500 participants (actual)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Amira Mohammed Abdel Mowgod, Assiut University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07043881
- Sponsor's protocol ID
- 4-2025-300625
- Acronym
- Hpylori/KAP
- Status last verified
- Jul 2025
- First submitted
- 21 Jun 2025
- Last updated
- 5 Nov 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 5 Nov 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Assessing Knowledge, Practices, Attitudes and Barriers of Puplic Population Regarding Helicobacter Pylori Infection in Upper Egypt: Cross- Sectional Study
- ClinicalTrials.gov ID
- NCT07043881
- Acronym / sponsor ID
- Hpylori/KAP / 4-2025-300625
- Study type
- Observational
- Recruitment status
- Completed
- Enrolment
- 500 participants (actual)
- Lead sponsor
- Assiut UniversityUniversity, hospital or other
- Study start
- 1 Oct 2026 (actual)
- Primary completion
- 1 Oct 2026 (actual)
- Study completion
- 1 Oct 2026 (actual)
- First posted
- 29 Jun 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications.
Evaluate attitudes toward the importance of testing, eradication, and antibiotic resistance concerns.
Describe current practices in diagnosis, treatment regimens, and follow-up. Identify barriers (e.g., access to tests, cost, training) impacting management.
Detailed description
Helicobacter pylori (H. pylori) is a gram-negative bacterium that colonizes the human stomach and is known for its role in the development of various gastrointestinal diseases. It is a major etiological factor in chronic peptic ulcer disease, which includes both gastric and duodenal ulcers.
The bacterium's ability to survive in the acidic environment of the stomach is facilitated by its production of urease, which neutralizes stomach acid. Chronic infection with H. pylori can lead to severe complications such as peptic ulcers, gastritis, and chronic indigestion (dyspepsia) making it a significant public health concern worldwide. It can lead to serious conditions such as stomach cancer (gastric adenocarcinoma) and mucosa-associated lymphoid tissue (MALT) lymphoma.
Helicobacter Pylori is one of the most common chronic infections that infect approximately 4.4 billion individuals worldwide. The area with the highest reported prevalence was reported in Africa (70.1%) while the lowest prevalence was reported in Switzerland (18.9%). The prevalence of HP shows large geographical variation with infection rates much higher in developing countries (in some areas > 85 %) than in Europe and North America (approximately 30%-40%). In various developing countries, more than 80% of the population is HP positive, even at young ages.
The significance of conducting research on H. pylori lies in its substantial burden on global health. Peptic ulcer disease and gastric cancer, both of which are associated with H. pylori infection, result in considerable morbidity and mortality.
Understanding the epidemiology, transmission dynamics, and pathogenic mechanisms of H. pylori is crucial for developing better prevention and treatment strategies. Additionally, research into antibiotic resistance patterns is essential for informing clinical practice and ensuring the continued efficacy of eradication regimens. Current research has extensively documented the global prevalence of H. pylori, with infection rates varying widely across different regions and populations.
Despite its widespread occurrence, there is a need to explore the knowledge and awareness of this infection within specific demographic segments, such as the urban population of Upper Egypt.
The level of awareness and knowledge about H. pylori in urban settings is crucial for public health initiatives, as it can inform targeted educational programs and interventions.
The urban population of the Upper Egypt, marked by diverse lifestyles and healthcare access, may exhibit unique patterns of awareness and knowledge regarding HP.
Factors such as cultural practices, dietary habits, and healthcare-seeking behavior can influence the prevalence of knowledge about the infection. Additionally, considering the rapid urbanization and lifestyle changes in Upper Egypt, exploring the awareness of H. pylori becomes increasingly relevant for developing effective preventive measures and promoting early detection.
Study design
- Observational model
- Case only
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 to 60 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult
- Study population
- Puplic population in Upper Egypt ( Assuit, Sohag, Minya, Qena, Luxor, Aswan) will answer validated, self-administered questionnaire (paper-based in Arabic).
Key inclusion criteria (3 listed)
- Non medical personnels.
- Age more than 18 years old e.g: patients, relatives of patients...etc.
- All persons who provided informed consent were included in this study.
Key exclusion criteria (1 listed)
- All medical staff members
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications.
Time frame: one year
Validated, self-administered questionnaire (paper-based in Arabic).
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 5 Nov 2026.
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
The record lists no contact. Use the official record to reach the sponsor.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Describe Current Practices in Hpylori Diagnosis, run by Assiut University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 5 Nov 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Assess non medical population knowledge of H. pylori epidemiology, diagnostic methods, treatment guidelines, and complications. (time frame: one year). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 Nov 2026.